KM257 + paclitaxel

KM257 + paclitaxel is a combination therapy under clinical investigation for the treatment of advanced HER2-positive or HER2-expressing solid tumors. KM257 is a bispecific antibody whose precise molecular targets are not fully specified in public sources, being developed to enhance antitumor effect, particularly when combined with chemotherapeutic agents. Paclitaxel is a well-established small molecule chemotherapeutic agent that stabilizes microtubules, thereby inhibiting cell division, and is commonly used in treating various cancers. The rational for the combination is to leverage the direct cytotoxicity of paclitaxel with the targeted immunotherapeutic or signaling-modulating effects of KM257. Early clinical trials are examining the safety and preliminary efficacy of KM257 in combination with paclitaxel and other cytotoxics in advanced cancer patients[3][4].